Stratos Wealth Partners LTD. cut its holdings in Thermo Fisher Scientific Inc (NYSE:TMO) by 2.9% in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 20,384 shares of the medical research company’s stock after selling 619 shares during the period. Stratos Wealth Partners LTD.’s holdings in Thermo Fisher Scientific were worth $3,556,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also added to or reduced their stakes in TMO. BlackRock Inc. boosted its holdings in Thermo Fisher Scientific by 2,692.1% in the 1st quarter. BlackRock Inc. now owns 22,988,885 shares of the medical research company’s stock worth $3,531,095,000 after buying an additional 22,165,530 shares during the period. C WorldWide Group Holding A S boosted its holdings in Thermo Fisher Scientific by 997.1% in the 1st quarter. C WorldWide Group Holding A S now owns 1,950,049 shares of the medical research company’s stock worth $299,527,000 after buying an additional 1,772,300 shares during the period. Harbour Capital Advisors LLC boosted its holdings in Thermo Fisher Scientific by 18,197.5% in the 2nd quarter. Harbour Capital Advisors LLC now owns 1,201,051 shares of the medical research company’s stock worth $6,884,000 after buying an additional 1,194,487 shares during the period. Veritas Asset Management LLP bought a new position in Thermo Fisher Scientific in the 1st quarter worth approximately $175,795,000. Finally, Vanguard Group Inc. boosted its holdings in Thermo Fisher Scientific by 2.7% in the 1st quarter. Vanguard Group Inc. now owns 25,971,301 shares of the medical research company’s stock worth $3,989,193,000 after buying an additional 695,079 shares during the period. 83.52% of the stock is owned by institutional investors.

In other Thermo Fisher Scientific news, VP Peter E. Hornstra sold 3,894 shares of the company’s stock in a transaction that occurred on Tuesday, September 5th. The shares were sold at an average price of $185.18, for a total value of $721,090.92. Following the completion of the transaction, the vice president now directly owns 19,751 shares in the company, valued at $3,657,490.18. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, Director Jim P. Manzi sold 11,318 shares of the company’s stock in a transaction that occurred on Friday, August 18th. The stock was sold at an average price of $172.94, for a total transaction of $1,957,334.92. Following the completion of the transaction, the director now owns 38,757 shares of the company’s stock, valued at $6,702,635.58. The disclosure for this sale can be found here. Over the last quarter, insiders sold 22,738 shares of company stock valued at $4,021,512. Company insiders own 0.49% of the company’s stock.

Shares of Thermo Fisher Scientific Inc (NYSE TMO) opened at 191.47 on Thursday. The stock has a market cap of $74.70 billion, a PE ratio of 33.36 and a beta of 1.05. Thermo Fisher Scientific Inc has a 52-week low of $139.07 and a 52-week high of $194.30. The stock’s 50 day moving average is $178.97 and its 200 day moving average is $169.99.

Thermo Fisher Scientific (NYSE:TMO) last posted its quarterly earnings results on Wednesday, July 26th. The medical research company reported $2.30 earnings per share for the quarter, topping the Zacks’ consensus estimate of $2.27 by $0.03. The business had revenue of $5 billion during the quarter, compared to analyst estimates of $4.92 billion. Thermo Fisher Scientific had a net margin of 11.80% and a return on equity of 15.97%. The company’s revenue was up 10.2% on a year-over-year basis. During the same period in the prior year, the business posted $2.03 earnings per share. Equities research analysts forecast that Thermo Fisher Scientific Inc will post $9.35 earnings per share for the current year.

The company also recently declared a quarterly dividend, which will be paid on Monday, October 16th. Shareholders of record on Friday, September 15th will be given a $0.15 dividend. The ex-dividend date is Thursday, September 14th. This represents a $0.60 dividend on an annualized basis and a dividend yield of 0.31%. Thermo Fisher Scientific’s payout ratio is currently 10.45%.

TMO has been the subject of several analyst reports. Citigroup Inc. reaffirmed a “buy” rating and issued a $201.00 price objective (up from $182.00) on shares of Thermo Fisher Scientific in a report on Monday, July 10th. BidaskClub downgraded shares of Thermo Fisher Scientific from a “strong-buy” rating to a “buy” rating in a report on Tuesday, June 27th. Deutsche Bank AG set a $200.00 price objective on shares of Thermo Fisher Scientific and gave the stock a “buy” rating in a report on Saturday, June 10th. Zacks Investment Research raised shares of Thermo Fisher Scientific from a “hold” rating to a “buy” rating and set a $199.00 price objective for the company in a report on Tuesday, July 11th. Finally, Bank of America Corporation reaffirmed a “buy” rating and issued a $210.00 price objective (up from $200.00) on shares of Thermo Fisher Scientific in a report on Friday, July 21st. Two research analysts have rated the stock with a hold rating, sixteen have assigned a buy rating and one has given a strong buy rating to the company. The stock has a consensus rating of “Buy” and a consensus target price of $193.19.

ILLEGAL ACTIVITY WARNING: This piece was first published by Daily Political and is the property of of Daily Political. If you are reading this piece on another domain, it was copied illegally and reposted in violation of United States and international copyright & trademark law. The correct version of this piece can be accessed at https://www.dailypolitical.com/2017/09/14/stratos-wealth-partners-ltd-has-3-56-million-position-in-thermo-fisher-scientific-inc-tmo.html.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc develops, manufactures and sells a range of products. The Company provides analytical instruments, equipment, reagents and consumables, software and services for research, manufacturing, analysis, discovery and diagnostics. It operates through four segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Services.

Want to see what other hedge funds are holding TMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Thermo Fisher Scientific Inc (NYSE:TMO).

Institutional Ownership by Quarter for Thermo Fisher Scientific (NYSE:TMO)

Receive News & Ratings for Thermo Fisher Scientific Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific Inc and related companies with MarketBeat.com's FREE daily email newsletter.